Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
LianBio Raises $310 Million to Bring Novel Medications to China
The financing was co-led by U.S. investors RA Capital and Venrock Healthcare Capital Partners and Chinese investor CMG-SDIC Capital.
LianBio has access to a broad selection of candidates from Perceptive's portfolio companies. However, in an interview with ChinaBio® Today (see story), LianBio executives said, "Our relationship with Perceptive only allows us to get in the door, it doesn't get us the deal. The team on the ground is what will win us the deals. We have to assure companies that their assets will be in good hands in
When LianBio broke out of stealth mode in August, it announced two initial deals. The company acquired
LianBio is led by an experienced executive team with deep regional experience, including Bing Li, CEO and Debra Yu, President and CBO.
LianBio's new financing was co-led by
“We are excited to partner with this world class group of investors who share our vision of accelerating broad access to transformative medicines for patients in
LianBio said the oversubscribed funding from well-known investors validates its global innovation mining platform. The company plans to build a pipeline that provides patients with transformative mechanisms and precision-based therapeutics.
See our other articles on LianBio.
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China